Ashland files investor presentation highlighting transformation into pure-play specialty chemicals company
Press Release
Ashland files investor presentation highlighting transformation into pure-play specialty chemicals company
Board and management are executing on strategic plan to deliver value
Urges shareholders to vote “FOR” Ashland’s highly qualified director nominees on the BLUE proxy card TODAY
Highlights of the presentation include:
- Ashland’s board and management team are executing a well-articulated plan and taking aggressive actions to position Ashland as a leading pure-play specialty chemicals company.
- Ashland’s strategy is working and yielding strong operating momentum and results.
- Ashland is delivering shareholder returns well in excess of the company’s proxy peers1, S&P MidCap 400 and S&P MidCap 400 Chemicals2.
- Ashland has a strong board with mix of key skills and balance of experiences, and has taken significant steps to refresh its composition.
- The Ashland board is a powerful advocate for investors and has a proven track record of delivering superior value.
- Cruiser’s nominees are not additive to Ashland’s board and do not offer the extended expertise that Ashland board members have.
Ashland’s investor presentation, along with other materials regarding the board’s recommendation for the 2019 Annual Meeting can be found at www.AshlandValue.com.
Ashland strongly recommends that its shareholders vote to support the Ashland directors at the upcoming 2019 Annual Meeting by voting the BLUE proxy card today "FOR" all 11 of Ashland’s qualified and experienced director nominees:
YOUR VOTE IS EXTREMELY IMPORTANT NO MATTER HOW MANY SHARES YOU OWN.
If you have any questions or require any assistance with voting your shares, please contact Ashland’s proxy solicitor:
Stockholders may call toll-free: 1 (877) 456-3402
Banks and Brokers may call collect: 1 (212) 750-5833
About Ashland
C-ASH
FORWARD-LOOKING STATEMENTS
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the
Ashland’s expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: the program to eliminate certain existing corporate and Specialty Ingredients expenses (including the possibility that such cost eliminations may not occur or may take longer to implement than anticipated), the expected divestiture of its Composites segment and the Marl BDO facility, and related merchant I&S products (including, in each case, the possibility that a transaction may not occur or that, if a transaction does occur, Ashland may not realize the anticipated benefits from such transaction), the impact of acquisitions and/or divestitures Ashland has made or may make, including the acquisition of Pharmachem (including the possibility that Ashland may not realize the anticipated benefits from such transactions); Ashland’s substantial indebtedness (including the possibility that such indebtedness and related restrictive covenants may adversely affect Ashland’s future cash flows, results of operations, financial condition and its ability to repay debt); Ashland’s ability to generate sufficient cash to finance its stock repurchase plans; severe weather, natural disasters, cyber events and legal proceedings and claims (including product recalls, environmental and asbestos matters); and without limitation, risks and uncertainties affecting Ashland that are described in Ashland’s most recent Form 10-K (including Item 1A Risk Factors) filed with the
IMPORTANT INFORMATION
On
CERTAIN INFORMATION REGARDING PARTICIPANTS
Ashland, its directors, director nominees and certain of its officers, including
FOR FURTHER INFORMATION:
Investor Relations: Media Relations:
Seth A. Mrozek
+1 (859) 815-3527 Steve Frankel /
samrozek@ashland.com (212) 355-4449
1 Proxy peers include
2 S&P MidCap 400 Chemicals index consists of 11 chemicals companies in the S&P MidCap 400 index:
Source: Ashland LLC